开郁正元散联合安罗替尼治疗晚期非小细胞肺癌30例临床观察

Clinical Observation on 30 Cases of Advanced Non-small Cell Lung Cancer Treated by Kaiyu Zhengyuan Powder(开郁正元散) Combined with Anrotinib

目的:研究开郁正元散联合安罗替尼治疗晚期非小细胞肺癌的有效性和安全性。方法:将60例晚期非小细胞肺癌脾虚痰湿证患者随机分为治疗组和对照组,每组30例,对照组患者口服安罗替尼治疗,治疗组患者在对照组基础上加用开郁正元散治疗,两组均以3周为1个疗程,2个疗程后进行病情评估,并对瘤体大小及KPS评分进行比较。结果:治疗组患者在瘤体大小改善方面优于对照组(P<0.05),KPS评分改善总有效率高于对照组(P<0.05)。用药安全方面,对照组3例出现高脂血症,3例出现高血压,1例出现口腔黏膜炎,治疗组2例出现手足皮肤反应,治疗组在用药安全方面优于对照组(P<0.05)。结论:开郁正元散能够有效地降低安罗替尼的副作用,提高治疗效果。

Objective:To study the efficacy and safety of Kaiyu Zhengyuan Powder combined with anlotinib in the treatment of advanced non-small cell lung cancer.Methods:Totally 60 cases of patients with advanced non-small cell lung cancer were randomly divided into treatment and control groups,30 cases in each group.The control group was treated with anrotidine hydrochloride capsules orally,and the treatment group was treated with Kaiyu Zhengyuan Powder on the basis of the control group,three weeks as a course of treatment.Both groups were evaluated after two courses of treatment,and the tumor size and KPS score were compared.Results:The treatment group showed better improvement of tumor size than control group(P<0.05),as well as higher total effective rate of improvement in KPS score than control group(P<0.05).In terms of drug safety,there were three cases of hypertension,three cases of hypertension and one case of oral mucositis in the control group,and two cases of hand foot skin reaction in treatment group.The treatment group was better than the control group in terms of medication safety(P<0.05).Conclusion:Kaiyu Zhengyuan Powder can effectively reduce the side effects of Anrotinib and improve the therapeutic effect.